Kane Biotech (KNE) AI Stock Analysis

• Market Cap: C$9.95M
• Dividend Yield: N/A
• Average Volume (3M): 137.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.19
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 165,771,560
• 10 Day Avg. Volume: 116,542
• 30 Day Avg. Volume: 137,847
• PEG Ratio: 0.13
• Price to Book (P/B): -1.67
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Kane Biotech's overall stock score is primarily impacted by its precarious financial position and valuation concerns, which are significant detractors. However, recent earnings growth, strategic partnerships, and positive corporate events provide a glimmer of potential recovery.

Kane Biotech Business Overview & Revenue Model

Company Description

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

How the Company Makes Money

Kane Biotech generates revenue through the commercialization of its proprietary technologies and products designed to combat biofilms. The company's revenue streams include product sales, licensing agreements, and strategic partnerships. Kane Biotech sells its products directly to consumers and through distribution channels, targeting both the healthcare and animal health markets. Additionally, the company enters into licensing agreements with other entities to utilize its biofilm technologies, which provides a stream of royalty income. Strategic partnerships with other companies also contribute to Kane Biotech's earnings, enabling collaborative development and expanded market reach.

Kane Biotech Financial Statement Overview

Summary

Kane Biotech's financial performance is weak, with challenges in revenue growth, negative profit margins, and a precarious balance sheet. The company faces ongoing financial instability with persistent losses and negative cash flows.

Income Statement

Kane Biotech's income statement reveals several challenges. The company has experienced inconsistent revenue growth, with a notable decrease in 2023 compared to previous years. The net profit margin remains negative, indicating ongoing losses, and both EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. These factors contribute to a low score, highlighting the need for improved revenue generation and cost management.

Balance Sheet

The balance sheet analysis shows significant financial instability. Kane Biotech has consistently negative stockholders' equity, indicating more liabilities than assets. The debt-to-equity ratio cannot be calculated due to negative equity, but high total debt levels suggest over-leverage. Moreover, the company’s equity ratio is negative, further signaling financial distress. These issues point to a precarious financial position, warranting a cautious approach.

Cash Flow

The cash flow statement reflects mixed results. Although the operating cash flow remains negative, indicating challenges in generating cash from core operations, there has been a notable influx of cash from financing activities in some years. Free cash flow is consistently negative, suggesting ongoing cash burn. The company needs to focus on improving operational cash flows to enhance financial stability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.08M	148.98K	2.67M	1.61M	1.34M
	Gross Profit
653.63K	109.47K	1.41M	568.44K	526.86K
	EBIT
-4.49M	-3.36M	-3.36M	-4.88M	-4.22M
	EBITDA
-3.71M	-3.23M	-2.95M	-4.25M	-3.65M
	Net Income Common Stockholders
-3.02M	-5.03M	-3.89M	-4.60M	-3.72M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
358.81K	749.25K	1.10M	1.15M	1.01M
	Total Assets
2.49M	5.68M	5.62M	6.13M	5.04M
	Total Debt
2.18M	9.26M	6.86M	4.71M	2.25M
	Net Debt
1.82M	8.51M	5.75M	3.56M	1.24M
	Total Liabilities
4.12M	14.09M	9.76M	7.70M	3.96M
	Stockholders Equity
-1.63M	-10.56M	-6.52M	-3.89M	-1.49M
Cash Flow		Free Cash Flow
-4.14M	-3.23M	-3.13M	-2.64M	-4.07M
	Operating Cash Flow
-4.11M	-3.22M	-3.04M	-2.29M	-3.94M
	Investing Cash Flow
10.27M	-116.14K	-107.55K	-373.55K	-166.11K
	Financing Cash Flow
-7.69M	2.98M	3.10M	2.81M	4.28M

Kane Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.08, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.36 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KNE.

Kane Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
KNE	47 Neutral	C$9.95M	―	-813.02%	―	―	―
BLAB	42 Neutral	C$9.74M	―	-175.45%	―	-3.93%	-575.24%
HEM	41 Neutral	C$21.80M	―	34.47%	―	―	43.45%
RVX		C$9.95M	―		―	―	―
SBM		C$15.29M	―		―	―	―
BETRF		$9.64M	―		―	―	―

Kane Biotech Corporate Events

Kane Biotech Reports Q1 2025 Results Amid Restructuring Efforts

Kane Biotech reported a significant increase in revenue for the first quarter of 2025, primarily from contract animal health manufacturing, despite a net loss. The company is undergoing a restructuring strategy to focus on its revyve™ product line and has implemented cost-reduction initiatives to strengthen its financial position. The departure of the CEO and subsequent legal action are notable developments, but the company remains committed to advancing its pipeline and creating long-term value for stakeholders.

Kane Biotech Secures $2.2 Million Through Private Placement and Insider Loan

Kane Biotech has successfully closed a private placement offering, raising $1.2 million through the issuance of 12 million shares to company insiders. Additionally, the company secured a $1 million unsecured loan from an insider, both transactions being classified as related party transactions. The funds will be used for working capital and general corporate purposes, potentially strengthening Kane Biotech’s financial position and operational capabilities.

Kane Biotech Reports 2024 Financials, Refocuses Strategy and Announces Leadership Change

Kane Biotech reported its financial results for the fourth quarter and full year 2024, showing a significant increase in revenue but a net loss for the year. The company is narrowing its strategic focus to its biofilm dispersion technology-based wound care products, particularly the revyve line, and is reorganizing its distribution approach in the U.S. market. A leadership change was also announced, with Dr. Robert Huizinga stepping in as interim CEO, following the departure of Marc Edwards.

Kane Biotech Revises Marketing Agreement with Outside the Box Capital

Kane Biotech has announced the termination of its previous service agreement with Outside the Box Capital Inc. (OTBC) and the initiation of a new agreement to enhance its marketing efforts within the financial community. This change was prompted by a policy update from the TSX Venture Exchange prohibiting the issuance of shares as compensation for investor relations services. Under the new agreement, OTBC will receive a cash payment and stock options, aligning with Kane Biotech’s strategic focus on broadening its media distribution and market awareness.

Kane Biotech Secures Approval for DispersinB® Acne Trial

Kane Biotech has received approval from the University of Miami Health System’s Internal Review Board to commence a clinical study of its DispersinB® Acne Cleanser for treating mild to moderate Acne Vulgaris. This trial, set to begin mid-year at the University of Miami Miller School of Medicine, marks a significant milestone for Kane Biotech as it continues to advance its mission of providing innovative dermatological solutions, potentially impacting millions of individuals suffering from acne.